Home
NLSPW
NLSPW News

Latest NLS Pharmaceutics Ltd. Warrant (NLSPW) News on July 27, 2024

MT Newswires

a month ago

NLS Pharmaceutics Announces Registered Direct Offering, Private Placement of Shares, Warrants

NLS Pharmaceutics Announces Registered Direct Offering

ACCESSWIRE

a month ago

NLS Pharmaceutics Announces Registered Direct Offering

MT Newswires

a month ago

Top Midday Gainers

MT Newswires

a month ago

NLS Pharmaceutics Reports Preclinical Data for Potential Parkinson's Disease Treatments; Shares Jump

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

ACCESSWIRE

a month ago

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

ACCESSWIRE

a month ago

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

ACCESSWIRE

a month ago

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model

ACCESSWIRE

2 months ago

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

ACCESSWIRE

2 months ago

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

ACCESSWIRE

3 months ago

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

ACCESSWIRE

4 months ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ACCESSWIRE

4 months ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

ACCESSWIRE

4 months ago

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

ACCESSWIRE

4 months ago

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

ACCESSWIRE

5 months ago

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ACCESSWIRE

5 months ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Notice of Deficiency with Nasdaq Continued Listing Requirements

ACCESSWIRE

6 months ago

Notice of Deficiency with Nasdaq Continued Listing Requirements

NLS Pharmaceutics CEO Issues Letter to Shareholders

ACCESSWIRE

7 months ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

ACCESSWIRE

8 months ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

NLS Pharmaceutics Announces Election of Additional Board Members

ACCESSWIRE

8 months ago

NLS Pharmaceutics Announces Election of Additional Board Members

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

ACCESSWIRE

8 months ago

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

ACCESSWIRE

8 months ago

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

Share on Social Networks: